Products
Vensobafusp Biosimilar Antibody Fusion Protein (Complement C5) for Research
Cat No.: GMP-Bios-INN-1453
Anti-C5 therapeutic antibody (Pre-made Vensobafusp biosimilar,Fusion Protein (whole mAb with protein)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vensobafusp (development codes KP104/P014) is an antibody fusion protein targeting complement factor C5, in which an engineered anti-C5 immunoglobulin G4 is fused to the N-terminal region of human complement factor H. It is developed by Kira Pharmaceuticals for paroxysmal nocturnal haemoglobinuria in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1453-1mg | 1mg | 3090 |
| GMP-Bios-INN-1453-10mg | 10mg | |
| GMP-Bios-INN-1453-100mg | 100mg | |
| GMP-Bios-INN-1453-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vensobafusp biosimilar, Fusion Protein (whole mAb with protein) targeting C5: Recombinant therapeutic protein targeting C5/CO5/Complement C5/C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 |
| INN Name | Vensobafusp |
| Target | C5 |
| Format | Fusion Protein (whole mAb with protein) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Kira Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Paroxysmal nocturnal haemoglobinuria |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
